Inhibikase Therapeutics, Inc.
IKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $38 | $78 | $73 | $56 |
| Short-Term Investments | $39 | $10 | $20 | $41 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $1 | $1 | $1 |
| Total Curr. Assets | $79 | $89 | $94 | $98 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | -$0 | -$0 | $0 |
| Total NC Assets | $1 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $80 | $89 | $94 | $99 |
| Liabilities | – | – | – | – |
| Payables | $1 | $3 | $2 | $1 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $6 | $6 | $7 | $3 |
| Total Curr. Liab. | $7 | $9 | $9 | $4 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | -$0 | $0 | $0 |
| Total NC Liab. | $0 | -$0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $7 | $9 | $9 | $4 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$130 | -$118 | -$108 | -$94 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $203 | $198 | $194 | $189 |
| Total Equity | $73 | $80 | $86 | $95 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $80 | $89 | $94 | $99 |
| Net Debt | -$38 | -$78 | -$73 | -$56 |